Using human cancer cell lines, UNC scientists identified various ways that HER2-positive breast cancer tumors resist therapy, and they discovered a potential combination therapy to overcome multiple mechanisms of resistance and kill cancer cells.
Bryan Roth and collaborator Raymond Stevens' Nature paper on "Molecular control of δ-opioid receptor signalling" was selected as one of the Best Breakthroughs in Signaling in 2014 in the Jan. 6 issue of Science Signaling. Gustavo Fenalti was first author on the paper.
Congratulations to Dr. Mauro Calabrese, Assistant Professor of Pharmacology, who has received the 2014 Basil O’Connor Scholar Research Award from the March of Dimes Foundation.
Two Pharmacology professors along with four other UNC professors elected Fellows of the AAAS.
The National Institute of Mental Health director Tom Insel recognized Byran L. Roth, MD, PhD, for his innovative research tool.
Graduate student Orrin Stone is creating molecular tools to pinpoint how and when cellular pathways trigger cell movement – or, in cancer, metastasis.
UNC Pharmacology & Toxicology Ranked #3 in the World by U.S. News & World Report
Joseph DeSimone, PhD, the Chancellor’s Eminent Professor of Chemistry and a joint Professor in the Department of Pharmacology, has been elected to the Institute of Medicine, one of the highest honors in the fields of health and medicine. This election represents the third time Desimone has been elected to a U.S. National Academy.
Roth’s research to create innovative tools for neuroscientists and discover potential targets for therapeutics has earned him one of the highest honors in the field of medicine.
Led by Bryan L. Roth, MD, PhD, three UNC labs will develop the next generation neuroscience tool-kit to accelerate novel treatments for neuropsychiatric and a host of other diseases. ~by Mark Derewicz
Bryan Roth and Gary Johnson Awarded NIH Grants From the NIH Illuminating the Druggable Genome Initiative
Drs. Bryan Roth and Gary Johnson receive 2 of 9 grants awarded by the NIH Illuminating the Druggable Genome Initiative which is supporting research to study 4 of the most commonly drug-targeted protein families